When is it OK to violate your cost basis to buy more shares of a company?

When is it OK to violate your cost basis to buy more shares of a company?


Nvidia CEO Jensen Huang,speaks at the Supermicro keynote presentation during the Computex conference in Taipei on June 1, 2023.

Walid Berrazeg | Sopa Images | Lightrocket | Getty Images

Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries.

This week’s question: The cardinal rule of discipline is to not violate cost basis and show patience to buy more high-quality stocks on pullback. How do you evaluate a flying stock which might not come back to levels of cost basis to add more? Recent examples include Nvidia (NVDA), Eli Lilly (LLY) and Tesla (TSLA). — Thanks, Ravi



Source

Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More
Making U.S. biotech more competitive with China’s could help rare disease patients, experts say
Health

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say

The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts […]

Read More